Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652257 · ClinicalTrials.gov registry record · Phase 1
A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
A Phase 1 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05652257 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 7 participants.
The verdict
NCT05652257, a Phase 1 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine the mass balance of total radioactivity and the routes of elimination by quantifying the urinary and fecal excretion of radioactivity following a single oral administration of \[14C\]-brensocatib, to characterize the pharmacokinetics (PK) of brensocatib in plasma and urine, PK of total radioactivity in plasma, whole blood, urine and to determine the blood-to-plasma ratios of total radioactivity.
Interventions
- DRUG [14C]-brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-08-13 |
| Est. Completion | 2021-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05652257
The ClinicalTrials.gov registry entry for NCT05652257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-brensocatib is the first listed.
NCT05652257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05652257 about?
NCT05652257 is a clinical study titled "A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants". The primary purpose of the study is to determine the mass balance of total radioactivity and the routes of elimination by quantifying the urinary and fecal excretion of radioactivity following a single oral administration of \[14C\]-brensocatib, to characterize the pharmacokinetics (PK) of brensocat...
What is the current status of trial NCT05652257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-08-13. Estimated completion is 2021-09-14.
What interventions are being tested in trial NCT05652257?
The interventions under investigation include: [14C]-brensocatib (DRUG).
Who is sponsoring clinical trial NCT05652257?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.